Mario Salmona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6749509/publications.pdf

Version: 2024-02-01

397 papers 17,684 citations

66 h-index 25230 113 g-index

403 all docs 403 docs citations

403 times ranked

20081 citing authors

#	Article	IF	CITATIONS
1	Antitumour drugs targeting tau R3 VQIVYK and Cys322 prevent seeding of endogenous tau aggregates by exogenous seeds. FEBS Journal, 2022, 289, 1929-1949.	2.2	7
2	The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102497.	1.7	4
3	Biochemical and biophysical features of disease-associated tau mutants V363A and V363I. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140755.	1.1	0
4	Toxicological impact of titanium dioxide nanoparticles and food-grade titanium dioxide (E171) on human and environmental health. Environmental Science: Nano, 2022, 9, 1199-1211.	2.2	17
5	Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice. Cancers, 2022, 14, 1814.	1.7	3
6	A Nanoscale Shape-Discovery Framework Supporting Systematic Investigations of Shape-Dependent Biological Effects and Immunomodulation. ACS Nano, 2022, 16, 1547-1559.	7.3	16
7	Food-Grade Titanium Dioxide Induces Toxicity in the Nematode Caenorhabditis elegans and Acute Hepatic and Pulmonary Responses in Mice. Nanomaterials, 2022, 12, 1669.	1.9	6
8	NMR-based Lavado cocoa chemical characterization and comparison with fermented cocoa varieties: Insights on cocoa's anti-amyloidogenic activity. Food Chemistry, 2021, 341, 128249.	4.2	15
9	Sleep inhibition induced by amyloid $\hat{\mathbf{e}}\hat{\mathbf{f}}^2$ oligomers is mediated by the cellular prion protein. Journal of Sleep Research, 2021, 30, e13187.	1.7	5
10	Nonphosphorylated tau slows down Aβ1–42 aggregation, binds to Aβ1–42 oligomers, and reduces Aβ1–4 toxicity. Journal of Biological Chemistry, 2021, 296, 100664.	⁴² 1.6	3
11	The similarity of inherited diseases (I): clinical similarity within the phenotypic series. BMC Medical Genomics, 2021, 14, 52.	0.7	0
12	Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. Journal of Controlled Release, 2021, 330, 587-598.	4.8	33
13	Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?. Biomolecules, 2021, 11, 855.	1.8	23
14	N-Terminally Truncated and Pyroglutamate-Modified AÎ ² Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimerâ \in ^M s Disease. Frontiers in Neuroscience, 2021, 15, 708119.	1.4	9
15	Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity. Viruses, 2021, 13, 1745.	1.5	2
16	Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2021366118.	3.3	4
17	Flavonoidâ€Derived Human Phenylâ€Î³â€Valerolactone Metabolites Selectively Detoxify Amyloidâ€Î² Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. Molecular Nutrition and Food Research, 2020, 64, e1900890.	1.5	24
18	Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease. ACS Chemical Neuroscience, 2020, 11, 367-372.	1.7	22

#	Article	IF	Citations
19	The similarity of inherited diseases (II): clinical and biological similarity between the phenotypic series. BMC Medical Genomics, 2020, 13, 139.	0.7	2
20	AÎ ² Beyond the AD Pathology: Exploring the Structural Response of Membranes Exposed to Nascent AÎ ² Peptide. International Journal of Molecular Sciences, 2020, 21, 8295.	1.8	7
21	Selenoprotein N is an endoplasmic reticulum calcium sensor that links luminal calcium levels to a redox activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21288-21298.	3.3	40
22	Neuronal Localization of SENP Proteins with Super Resolution Microscopy. Brain Sciences, 2020, 10, 778.	1.1	8
23	Quantitative analysis of proteins which are members of the same protein complex but cause locus heterogeneity in disease. Scientific Reports, 2020, 10, 10423.	1.6	3
24	A portable optical-fibre-based surface plasmon resonance biosensor for the detection of therapeutic antibodies in human serum. Scientific Reports, 2020, 10, 11154.	1.6	82
25	Increased transcription of transglutaminase 1 mediates neuronal death in in vitro models of neuronal stress and $\hat{Al^2}1\hat{a}\in$ "42-mediated toxicity. Neurobiology of Disease, 2020, 140, 104849.	2.1	10
26	Synthesis and Molecular Modelling Studies of New 1,3-Diaryl-5-Oxo-Proline Derivatives as Endothelin Receptor Ligands. Molecules, 2020, 25, 1851.	1.7	2
27	Cellulose nanocrystals: a multimodal tool to enhance the targeted drug delivery against bone disorders. Nanomedicine, 2020, 15, 2271-2285.	1.7	5
28	Super-Resolution Imaging to Study Co-Localization of Proteins and Synaptic Markers in Primary Neurons. Journal of Visualized Experiments, 2020, , .	0.2	2
29	Super Resolution Microscopy of SUMO Proteins in Neurons. Frontiers in Cellular Neuroscience, 2019, 13, 486.	1.8	19
30	[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT7 receptor. European Journal of Medicinal Chemistry, 2019, 183, 111690.	2.6	4
31	The Anti-Amyloidogenic Action of Doxycycline: A Molecular Dynamics Study on the Interaction with A \hat{l}^2 42. International Journal of Molecular Sciences, 2019, 20, 4641.	1.8	28
32	Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. ACS Nano, 2019, 13, 4410-4423.	7.3	47
33	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. Scientific Reports, 2019, 9, 2064.	1.6	53
34	Dreaming of a New World Where Alzheimer's Is a Treatable Disorder. Frontiers in Aging Neuroscience, 2019, 11, 317.	1.7	14
35	Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs. Pharmaceutics, 2019, 11, 658.	2.0	17
36	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 32-40.	1.3	46

#	Article	IF	Citations
37	Review: PrP 106â€126 – 25 years after. Neuropathology and Applied Neurobiology, 2019, 45, 430-440.	1.8	19
38	bioNMR-based identification of natural anti-A \hat{l}^2 compounds in Peucedanum ostruthium. Bioorganic Chemistry, 2019, 83, 76-86.	2.0	26
39	p17 from HIV induces brain endothelial cell angiogenesis through EGFR-1-mediated cell signalling activation. Laboratory Investigation, 2019, 99, 180-190.	1.7	6
40	Identification of amino acid residues critical for the B cell growth-promoting activity of HIV-1 matrix protein p17 variants. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 13-24.	1.1	20
41	In Situ Tissue Labeling of Cerebral Amyloid Using HIV-Related Tat Peptide. Molecular Neurobiology, 2018, 55, 6834-6840.	1.9	10
42	Mutagenicity, anticancer activity and blood brain barrier: similarity and dissimilarity of molecular alerts. Toxicology Mechanisms and Methods, 2018, 28, 321-327.	1.3	12
43	NMR-driven identification of anti-amyloidogenic compounds in green and roasted coffee extracts. Food Chemistry, 2018, 252, 171-180.	4.2	47
44	Use of quasi-SMILES to model biological activity of "micelle–polymer―samples. Structural Chemistry, 2018, 29, 1213-1223.	1.0	10
45	Translational Research in Alzheimer's and Prion Diseases. Journal of Alzheimer's Disease, 2018, 62, 1247-1259.	1.2	7
46	V363I and V363A mutated tau affect aggregation and neuronal dysfunction differently in C. elegans. Neurobiology of Disease, 2018, 117, 226-234.	2.1	11
47	Realistic Evaluation of Titanium Dioxide Nanoparticle Exposure in Chewing Gum. Journal of Agricultural and Food Chemistry, 2018, 66, 6860-6868.	2.4	32
48	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiology of Aging, 2018, 70, 128-139.	1.5	52
49	Safety and Toxicology of Magnolol and Honokiol. Planta Medica, 2018, 84, 1151-1164.	0.7	151
50	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by \hat{l}^2 -amyloid oligomers in an acute mouse model of Alzheimer's disease. Brain, Behavior, and Immunity, 2017, 60, 188-197.	2.0	123
51	Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. Antioxidants and Redox Signaling, 2017, 27, 567-582.	2.5	38
52	Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-concept. European Journal of Pharmaceutical Sciences, 2017, 101, 140-148.	1.9	27
53	QSAR model for blood-brain barrier permeation. Journal of Pharmacological and Toxicological Methods, 2017, 88, 7-18.	0.3	33
54	Pathogenic AÎ 2 A2V versus protective AÎ 2 A2T mutation: Early stage aggregation and membrane interaction. Biophysical Chemistry, 2017, 229, 11-18.	1.5	16

#	Article	lF	Citations
55	Applicability of [11 C]PIB micro-PET imaging for inÂvivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiology of Aging, 2017, 57, 84-94.	1.5	17
56	Influence of Size and Shape on the Anatomical Distribution of Endotoxin-Free Gold Nanoparticles. ACS Nano, 2017, 11, 5519-5529.	7.3	131
57	Inhibition of ${\rm A\hat{I}^2}$ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry. ACS Chemical Neuroscience, 2017, 8, 1767-1778.	1.7	72
58	A simple headspace gas chromatography/mass spectrometry method for the quantitative determination of the release of the antioxidants butylated hydroxyanisole and butylated hydroxytoluene from chewing gum. Rapid Communications in Mass Spectrometry, 2017, 31, 859-864.	0.7	16
59	Humanin Specifically Interacts with Amyloid- \hat{l}^2 Oligomers and Counteracts Their in vivo Toxicity. Journal of Alzheimer's Disease, 2017, 57, 857-871.	1.2	23
60	New N- and O-arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT7 and 5-HT1A receptor ligands: Synthesis, structure-activity relationships, and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2017, 25, 1250-1259.	1.4	21
61	Biocompatible Polymer Nanoformulation To Improve the Release and Safety of a Drug Mimic Molecule Detectable via ICP-MS. Molecular Pharmaceutics, 2017, 14, 124-134.	2.3	20
62	HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders. Scientific Reports, 2017, 7, 10313.	1.6	28
63	The A2V mutation as a new tool for hindering $\hat{Al^2}$ aggregation: A neutron and x-ray diffraction study. Scientific Reports, 2017, 7, 5510.	1.6	9
64	Single particle extinction and scattering optical method unveils in real time the influence of the blood components on polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2597-2603.	1.7	7
65	Flavonoids and Their Glycosides as Antiâ€amyloidogenic Compounds: Aβ1–42 Interaction Studies to Gain New Insights into Their Potential for Alzheimer's Disease Prevention and Therapy. Chemistry - an Asian Journal, 2017, 12, 67-75.	1.7	31
66	Utilization of the Monte Carlo Method to Build up QSAR Models for Hemolysis and Cytotoxicity of Antimicrobial Peptides. Current Drug Discovery Technologies, 2017, 14, 229-243.	0.6	17
67	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers. Journal of Alzheimer's Disease, 2016, 53, 1485-1497.	1.2	12
68	Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib. PLoS ONE, 2016, 11, e0152465.	1.1	45
69	Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT7R selective ligands over 5-HT1AR. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4052-4056.	1.0	18
70	Synthesis and Preliminary Biological Evaluation of Fluorescent Glycofused Tricyclic Derivatives of Amyloid βâ€Peptide Ligands. European Journal of Organic Chemistry, 2016, 2016, 1660-1664.	1.2	4
71	Structural Modifications of <i>cis</i> â€Glycofused Benzopyran Compounds and Their Influence on the Binding to Amyloidâ€Î² Peptide. Chemistry - an Asian Journal, 2016, 11, 299-309.	1.7	16
72	Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Scientific Reports, 2016, 6, 20949.	1.6	26

#	Article	lF	Citations
73	L16â€Identifying a therapeutic regimen for cholesterol delivery to huntington's disease brain. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A95.2-A95.	0.9	O
74	Amyloid \hat{l}^2 Peptides in interaction with raft-mime model membranes: a neutron reflectivity insight. Scientific Reports, 2016, 6, 20997.	1.6	31
75	Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study. Scientific Reports, 2016, 6, 33444.	1.6	34
76	Cellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17. Scientific Reports, 2016, 6, 38027.	1.6	14
77	Monte Carlo method for predicting of cardiac toxicity: hERG blocker compounds. Toxicology Letters, 2016, 250-251, 42-46.	0.4	31
78	Betaâ€amyloid 1â€42 monomers, but not oligomers, produce <scp>PHF</scp> â€like conformation of Tau protein. Aging Cell, 2016, 15, 914-923.	3.0	27
79	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model. Nano Research, 2016, 9, 2190-2201.	5.8	13
80	The new β amyloid-derived peptide Aβ1–6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity. Neurobiology of Disease, 2016, 88, 75-84.	2.1	17
81	An early developmental vertebrate model for nanomaterial safety: bridging cell-based and mammalian toxicity assessment. Nanomedicine, 2016, 11, 643-656.	1.7	21
82	Internalization of nanopolymeric tracers does not alter characteristics of placental cells. Journal of Cellular and Molecular Medicine, 2016, 20, 1036-1048.	1.6	4
83	The cell-permeable $\hat{Al^2}$ 1-6A2VTAT(D) peptide reverts synaptopathy induced by $\hat{Al^2}$ 1-42wt. Neurobiology of Disease, 2016, 89, 101-111.	2.1	19
84	Clusterin Binds to Aβ1–42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation. Journal of Biological Chemistry, 2016, 291, 6958-6966.	1.6	99
85	Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer. Biomacromolecules, 2016, 17, 744-755.	2.6	19
86	The hunt for brain $A\hat{l}^2$ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 43-52.	1.7	46
87	Doxycycline hinders phenylalanine fibril assemblies revealing a potential novel therapeutic approach in phenylketonuria. Scientific Reports, 2015, 5, 15902.	1.6	33
88	Investigation of Functionalized Poly(<i>N</i> NNòâ€dimethylacrylamide)â€ <i>block</i> â€polystyrene Nanoparticles As Novel Drug Delivery System to Overcome the Blood–Brain Barrier In Vitro. Macromolecular Bioscience, 2015, 15, 1687-1697.	2.1	24
89	NO-donor thiacarbocyanines as multifunctional agents for Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2015, 23, 4688-4698.	1.4	21
90	Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT1A and 5-HT7 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1427-1430.	1.0	22

#	Article	IF	Citations
91	Organ Distribution and Bone Tropism of Cellulose Nanocrystals in Living Mice. Biomacromolecules, 2015, 16, 2862-2871.	2.6	72
92	Multigram Synthesis and in Vivo Efficacy Studies of a Novel Multitarget Anti-Alzheimer's Compound. Molecules, 2015, 20, 4492-4515.	1.7	17
93	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. Stem Cell Research, 2015, 15, 243-253.	0.3	19
94	Chemerin Produced By Mesenchymal Stromal Cells (MSC) Is an Important Factor for In Vivo macrophage Migration. Blood, 2015, 126, 1195-1195.	0.6	0
95	<i>Cis</i> â€Glycoâ€Fused Benzopyran Derivatives as Hit Compounds for the Development of Therapeutic and Diagnostic Tools against Neurodegenerative Diseases. ChemPlusChem, 2014, 79, 835-843.	1.3	15
96	Multifunctional Liposomes Reduce Brain \hat{l}^2 -Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models. Journal of Neuroscience, 2014, 34, 14022-14031.	1.7	141
97	A New Surface Plasmon Resonance-Based Immunoassay for Rapid, Reproducible and Sensitive Quantification of Pentraxin-3 in Human Plasma. Sensors, 2014, 14, 10864-10875.	2.1	16
98	Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans. Worm, 2014, 3, e965590.	1.0	9
99	A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma. Nanotechnology, 2014, 25, 335706.	1.3	22
100	Integrated multiplatform method for in vitro in	1.3	19
101	Blood protein coating of gold nanoparticles as potential tool for organ targeting. Biomaterials, 2014, 35, 3455-3466.	5.7	111
102	Determination of tissue levels of a neuroprotectant drug: The cell permeable JNK inhibitor peptide. Journal of Pharmacological and Toxicological Methods, 2014, 70, 55-61.	0.3	17
103	Monomeric Aβ1–42 and RAGE: key players in neuronal differentiation. Neurobiology of Aging, 2014, 35, 1301-1308.	1.5	28
104	Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiology of Disease, 2014, 62, 218-232.	2.1	110
105	Synthesis and evaluation of a 18F-curcumin derivate for \hat{I}^2 -amyloid plaque imaging. Bioorganic and Medicinal Chemistry, 2014, 22, 2753-2762.	1.4	32
106	Mono and Dually Decorated Nanoliposomes for Brain Targeting, In Vitro and In Vivo Studies. Pharmaceutical Research, 2014, 31, 1275-1289.	1.7	59
107	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	4.9	157
108	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. Journal of Medicinal Chemistry, 2014, 57, 9578-9597.	2.9	46

#	Article	IF	Citations
109	The Peculiar Role of the A2V Mutation in Amyloid- \hat{l}^2 (A \hat{l}^2) $1\hat{a}$ \in "42 Molecular Assembly. Journal of Biological Chemistry, 2014, 289, 24143-24152.	1.6	54
110	Natural Compounds against Neurodegenerative Diseases: Molecular Characterization of the Interaction of Catechins from Green Tea with Aβ1–42, PrP106–126, and Ataxinâ€3 Oligomers. Chemistry - A European Journal, 2014, 20, 13793-13800.	1.7	38
111	Structure–activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT7 and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2014, 85, 716-726.	2.6	33
112	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol. EJNMMI Research, 2014, 4, 37.	1.1	22
113	An integrated approach for the systematic evaluation of polymeric nanoparticles in healthy and diseased organisms. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	12
114	c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death and Disease, 2014, 5, e1019-e1019.	2.7	88
115	<i>In Vivo</i> Fate of Avidin-Nucleic Acid Nanoassemblies as Multifunctional Diagnostic Tools. ACS Nano, 2014, 8, 175-187.	7.3	36
116	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiology of Aging, 2014, 35, 408-417.	1.5	36
117	Expression of A2V-mutated $\hat{Al^2}$ in Caenorhabditis elegans results in oligomer formation and toxicity. Neurobiology of Disease, 2014, 62, 521-532.	2.1	30
118	A Caenorhabditis elegans–based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood, 2014, 123, 3543-3552.	0.6	122
119	Chemerin As a New Potential Player in the Immunoregulatory Activity of Mesenchymal Stromal Cells. Blood, 2014, 124, 1590-1590.	0.6	O
120	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	1.4	24
121	Novel approaches for studying amyloidogenic peptides/proteins. Current Opinion in Pharmacology, 2013, 13, 797-801.	1.7	15
122	Biocompatible fluorescent nanoparticles for <i>in vivo </i> stem cell tracking. Nanotechnology, 2013, 24, 245603.	1.3	29
123	A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses. Journal of Medicinal Chemistry, 2013, 56, 5987-6006.	2.9	76
124	Fluorescent amyloid & Deptide ligand derivatives as potential diagnostic tools for Alzheimer amp; rsquo; s disease. Pure and Applied Chemistry, 2013, 85, 1813-1823.	0.9	11
125	Soluble $\hat{Al^2}$ oligomer-induced synaptopathy: c-Jun N-terminal kinase's role. Journal of Molecular Cell Biology, 2013, 5, 277-279.	1.5	28
126	Longitudinal Amyloid Imaging in Mouse Brain with ¹¹ C-PIB: Comparison of APP23, Tg2576, and APP _{swe} -PS1 _{dE9} Mouse Models of Alzheimer Disease. Journal of Nuclear Medicine, 2013, 54, 1434-1441.	2.8	71

#	Article	IF	Citations
127	Oleuropein Aglycone Protects Transgenic C. elegans Strains Expressing AÎ ² 42 by Reducing Plaque Load and Motor Deficit. PLoS ONE, 2013, 8, e58893.	1.1	116
128	PaCS Is a Novel Cytoplasmic Structure Containing Functional Proteasome and Inducible by Cytokines/Trophic Factors. PLoS ONE, 2013, 8, e82560.	1.1	13
129	Applications of Surface Plasmon Resonance (SPR) for the Characterization of Nanoparticles Developed for Biomedical Purposes. Sensors, 2012, 12, 16420-16432.	2.1	59
130	Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2012, 71, 840-854.	0.9	64
131	New mutations in MAPT gene causing frontotemporal lobar degeneration: biochemical and structural characterization. Neurobiology of Aging, 2012, 33, 834.e1-834.e6.	1.5	28
132	Specific Recognition of Biologically Active Amyloid- \hat{l}^2 Oligomers by a New Surface Plasmon Resonance-based Immunoassay and an in Vivo Assay in Caenorhabditis elegans. Journal of Biological Chemistry, 2012, 287, 27796-27805.	1.6	52
133	βâ€Amyloid 1â€42 induces physiological transcriptional regulation of BACE1. Journal of Neurochemistry, 2012, 122, 1023-1031.	2.1	22
134	Good gene, bad gene: New APP variant may be both. Progress in Neurobiology, 2012, 99, 281-292.	2.8	31
135	Huprine–Tacrine Heterodimers as Anti-Amyloidogenic Compounds of Potential Interest against Alzheimer's and Prion Diseases. Journal of Medicinal Chemistry, 2012, 55, 661-669.	2.9	90
136	In Vitro Aggregation Behavior of a Non-Amyloidogenic λ Light Chain Dimer Deriving from U266 Multiple Myeloma Cells. PLoS ONE, 2012, 7, e33372.	1.1	21
137	The effect of chewing gum on gastric fluid volume and pH in healthy subjects. Nutrafoods, 2012, 11, 25-27.	0.5	4
138	Colloidal stability of polymeric nanoparticles in biological fluids. Journal of Nanoparticle Research, 2012, 14, 920.	0.8	126
139	Longitudinal Tracking of Human Fetal Cells Labeled with Super Paramagnetic Iron Oxide Nanoparticles in the Brain of Mice with Motor Neuron Disease. PLoS ONE, 2012, 7, e32326.	1.1	28
140	C. elegans Expressing Human \hat{l}^2 2-Microglobulin: A Novel Model for Studying the Relationship between the Molecular Assembly and the Toxic Phenotype. PLoS ONE, 2012, 7, e52314.	1.1	21
141	Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. Organic and Biomolecular Chemistry, 2011, 9, 5137.	1.5	44
142	Tetracycline prevents $\hat{Al^2}$ oligomer toxicity through an atypical supramolecular interaction. Organic and Biomolecular Chemistry, 2011, 9, 463-472.	1.5	52
143	Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. Journal of Biotechnology, 2011, 156, 341-346.	1.9	92
144	Curcumin derivatives as new ligands of $\hat{Al^2}$ peptides. Journal of Biotechnology, 2011, 156, 317-324.	1.9	31

#	Article	IF	CITATIONS
145	The Molecular Assembly of Amyloid \hat{Al}^2 Controls Its Neurotoxicity and Binding to Cellular Proteins. PLoS ONE, 2011, 6, e24909.	1.1	39
146	Interactions of the prion peptide (PrP 106-126) with brain capillary endothelial cells: coordinated cell killing and remodeling of intercellular junctions. Journal of Neurochemistry, 2011, 116, 467-475.	2.1	11
147	Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 551-559.	1.7	149
148	cis-Glyco-fused benzopyran compounds as new amyloid- \hat{l}^2 peptide ligands. Chemical Communications, 2011, 47, 10266.	2.2	40
149	Curcumin-decorated nanoliposomes with very high affinity for amyloid- \hat{l}^2 1-42 peptide. Biomaterials, 2011, 32, 1635-1645.	5.7	198
150	Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic $A\hat{l}^21\hat{a}\in 42$ peptide, synthesized by depsi-peptide technique. Biosensors and Bioelectronics, 2011, 26, 2772-2775.	5.3	36
151	A modified protocol to prepare seed-free starting solutions of amyloid-β (Aβ)1–40 and Aβ1–42 from the corresponding depsipeptides. Analytical Biochemistry, 2011, 411, 297-299.	1.1	38
152	The binding affinity of anti-AÎ ² 1-42ÂMAb-decorated nanoliposomes to AÎ ² 1-42Âpeptides inÂvitro and to amyloid deposits in post-mortem tissue. Biomaterials, 2011, 32, 5489-5497.	5.7	76
153	Effect of Tetracyclines on the Dynamics of Formation and Destructuration of \hat{l}^2 2-Microglobulin Amyloid Fibrils. Journal of Biological Chemistry, 2011, 286, 2121-2131.	1.6	87
154	Expression of Mutant or Cytosolic PrP in Transgenic Mice and Cells Is Not Associated with Endoplasmic Reticulum Stress or Proteasome Dysfunction. PLoS ONE, 2011, 6, e19339.	1.1	32
155	Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathologica, 2010, 120, 803-812.	3.9	61
156	Polyunsaturated Fatty Acids Protect Against Prion-Mediated Synapse Damage InÂVitro. Neurotoxicity Research, 2010, 17, 203-214.	1.3	13
157	Tetracycline and its analogues protect Caenorhabditis elegans from \hat{l}^2 amyloid-induced toxicity by targeting oligomers. Neurobiology of Disease, 2010, 40, 424-431.	2.1	102
158	Solid-state stability studies of cholecystokinin (CCK-4) peptide under nonisothermal conditions using thermal analysis, chromatography and mass spectrometry. European Journal of Pharmaceutical Sciences, 2010, 39, 263-271.	1.9	6
159	Preparation and characterization of lipid-based nanoparticles binding with high affinity amyloid- \hat{l}^2 1-42 peptide. Journal of Biotechnology, 2010, 150, 27-27.	1.9	2
160	Lipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide. Biomaterials, 2010, 31, 6519-6529.	5.7	190
161	Mutant Prion Protein Expression Is Associated with an Alteration of the Rab GDP Dissociation Inhibitor \hat{l}_{\pm} (GDI)/Rab11 Pathway. Molecular and Cellular Proteomics, 2010, 9, 611-622.	2.5	35
162	Synthetic amyloid- \hat{l}^2 oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2295-2300.	3.3	435

#	Article	IF	Citations
163	New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid- \hat{l}^2 Peptide. Analytical Chemistry, 2010, 82, 10083-10089.	3.2	50
164	A New Fluorogenic Peptide Determines Proteasome Activity in Single Cells. Journal of Medicinal Chemistry, 2010, 53, 7452-7460.	2.9	20
165	Tetracyclines and Prion Infectivity. Infectious Disorders - Drug Targets, 2009, 9, 23-30.	0.4	48
166	Characterization of Detergent-Insoluble Proteins in ALS Indicates a Causal Link between Nitrative Stress and Aggregation in Pathogenesis. PLoS ONE, 2009, 4, e8130.	1.1	101
167	Glimepiride Reduces the Expression of PrPC, Prevents PrPSc Formation and Protects against Prion Mediated Neurotoxicity. PLoS ONE, 2009, 4, e8221.	1.1	24
168	JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiology of Disease, 2009, 33, 518-525.	2.1	134
169	ST1859 reduces prion infectivity and increase survival in experimental scrapie. Archives of Virology, 2009, 154, 1539-1544.	0.9	2
170	Spontaneous βâ€helical fold in prion protein: The case of PrP(82â€146). Proteins: Structure, Function and Bioinformatics, 2009, 75, 964-976.	1.5	6
171	The SIRT1 activator resveratrol protects SKâ€Nâ€BE cells from oxidative stress and against toxicity caused by αâ€synuclein or amyloidâ€Î² (1â€42) peptide. Journal of Neurochemistry, 2009, 110, 1445-1456.	2.1	241
172	Proteomic Profiling of Cervical and Lumbar Spinal Cord Reveals Potential Protective Mechanisms in the Wobbler Mouse, a Model of Motor Neuron Degeneration. Journal of Proteome Research, 2009, 8, 5229-5240.	1.8	14
173	c-Jun N-terminal kinase binding domain–dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons. Neuroscience, 2009, 159, 94-103.	1.1	37
174	Acetylcholinesterase as an amyloid enhancing factor in PrP82-146 aggregation process. Molecular and Cellular Neurosciences, 2009, 40, 217-224.	1.0	24
175	A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis. Science, 2009, 323, 1473-1477.	6.0	357
176	Overcoming synthetic $\hat{Al^2}$ peptide aging: a new approach to an age-old problem. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 71-80.	1.4	36
177	The anti-fibrillogenic activity of tetracyclines on PrP 106–126: a 3D-QSAR study. Journal of Molecular Modeling, 2008, 14, 987-994.	0.8	20
178	Conformational Plasticity of the Gerstmann–Strässler–Scheinker Disease Peptide as Indicated by Its Multiple Aggregation Pathways. Journal of Molecular Biology, 2008, 381, 1349-1361.	2.0	56
179	Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82–146 and Aβ1–42. Neuropharmacology, 2008, 54, 934-943.	2.0	22
180	Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biology, 2008, 6, 39.	1.7	13

#	Article	IF	CITATIONS
181	The Efficacy of Tetracyclines in Peripheral and Intracerebral Prion Infection. PLoS ONE, 2008, 3, e1888.	1.1	94
182	Neurotoxic and Gliotrophic Activity of a Synthetic Peptide Homologous to Gerstmann-Straussler-Scheinker Disease Amyloid Protein. Journal of Neuroscience, 2007, 27, 1576-1583.	1.7	35
183	Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochemical and Biophysical Research Communications, 2007, 353, 719-725.	1.0	72
184	Cytoplasmic Domain of Human Myelin Protein Zero Likely Folded as \hat{l}^2 -Structure in Compact Myelin. Biophysical Journal, 2007, 92, 1585-1597.	0.2	33
185	Cytoplasmic Domain of Zebrafish Myelin Protein Zero: Adhesive Role Depends on β-Conformation. Biophysical Journal, 2007, 93, 3515-3528.	0.2	10
186	Aggregation/Fibrillogenesis of Recombinant Human Prion Protein and Gerstmanna^'StrAषusslera^'Scheinker Disease Peptides in the Presence of Metal Ions. Biochemistry, 2006, 45, 6724-6732.	1.2	38
187	Conformational Polymorphism of the PrP106â^'126 Peptide in Different Environments:  A Molecular Dynamics Study. Journal of Physical Chemistry B, 2006, 110, 1423-1428.	1.2	35
188	Acetylcholinesterase triggers the aggregation of PrP 106–126. Biochemical and Biophysical Research Communications, 2006, 346, 89-94.	1.0	24
189	Redox regulation of cyclophilin A by glutathionylation. Proteomics, 2006, 6, 817-825.	1.3	43
190	Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity. Proteomics, 2006, 6, 2823-2834.	1.3	19
191	Effect of Acetylcholinesterase Inhibitors on AChE-Induced PrP106-126 Aggregation. Journal of Molecular Neuroscience, 2006, 30, 89-90.	1.1	6
192	$\hat{Gl}\pm 13$ mediates activation of the cytosolic phospholipase $\hat{A2l}\pm$ through fine regulation of ERK phosphorylation. Cellular Signalling, 2006, 18, 2200-2208.	1.7	21
193	Insoluble Mutant SOD1 Is Partly Oligoubiquitinated in Amyotrophic Lateral Sclerosis Mice. Journal of Biological Chemistry, 2006, 281, 33325-33335.	1.6	86
194	Gerstmann-Strässler-Scheinker Disease Amyloid Protein Polymerizes According to the "Dock-and-Lock―Model. Journal of Biological Chemistry, 2006, 281, 843-849.	1.6	33
195	Tetracycline and its analogues as inhibitors of amyloid fibrils: searching for a geometrical pharmacophore by theoretical investigation of their conformational behavior in aqueous solution. Journal of Molecular Modeling, 2005, 11 , 17 -25.	0.8	20
196	Role of Plasminogen in Propagation of Scrapie. Journal of Virology, 2005, 79, 11225-11230.	1.5	18
197	Protein Nitration in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Journal of Biological Chemistry, 2005, 280, 16295-16304.	1.6	168
198	The neurotoxicity of prion protein (PrP) peptide 106–126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Molecular and Cellular Neurosciences, 2005, 28, 165-176.	1.0	55

#	Article	IF	CITATIONS
199	Hereditary Prion Protein Amyloidoses. , 2005, , 83-109.		1
200	Regulation and Biochemistry of Mouse Molybdo-flavoenzymes. Journal of Biological Chemistry, 2004, 279, 8668-8683.	1.6	39
201	Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity. Journal of Biological Chemistry, 2004, 279, 14983-14990.	1.6	124
202	The Aldehyde Oxidase Gene Cluster in Mice and Rats. Journal of Biological Chemistry, 2004, 279, 50482-50498.	1.6	56
203	An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Analytical Biochemistry, 2004, 333, 372-380.	1.1	25
204	P3-357 Structural properties of gerstmann-StrÃ u ssler-Scheinker disease amyloid protein. Neurobiology of Aging, 2004, 25, S457.	1.5	0
205	P4-415 ST1859 reduces prion infectivity and increase survival in experimental scrapie. Neurobiology of Aging, 2004, 25, S592.	1.5	0
206	Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. Journal of Neuroinflammation, 2004, 1, 4.	3.1	73
207	The role of platelet activating factor in prion and amyloid- \hat{l}^2 neurotoxicity. NeuroReport, 2004, 15, 509-513.	0.6	39
208	Cytotoxicity of PrP Peptides., 2004, , 176-197.		1
208	Cytotoxicity of PrP Peptides. , 2004, , 176-197. Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941.	1.3	21
		1.3	
209	Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941.		21
209	Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941. Therapeutic approaches to prion diseases. Clinics in Laboratory Medicine, 2003, 23, 187-208.	0.7	21
209 210 211	Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941. Therapeutic approaches to prion diseases. Clinics in Laboratory Medicine, 2003, 23, 187-208. Evaluation of Quinacrine Treatment for Prion Diseases. Journal of Virology, 2003, 77, 8462-8469. Structural Properties of Gerstmann-StrÄgssler-Scheinker Disease Amyloid Protein. Journal of	0.7	21 14 190
209 210 211 212	Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941. Therapeutic approaches to prion diseases. Clinics in Laboratory Medicine, 2003, 23, 187-208. Evaluation of Quinacrine Treatment for Prion Diseases. Journal of Virology, 2003, 77, 8462-8469. Structural Properties of Gerstmann-StrÃussler-Scheinker Disease Amyloid Protein. Journal of Biological Chemistry, 2003, 278, 48146-48153. In vitro Evaluation of the Anti-prionic Activity of Newly Synthesized Congo Red Derivatives.	0.7 1.5 1.6	21 14 190 75
210 211 212 213	Quinacrine blocks PrP (106-126)-formed channels. Journal of Neuroscience Research, 2003, 74, 934-941. Therapeutic approaches to prion diseases. Clinics in Laboratory Medicine, 2003, 23, 187-208. Evaluation of Quinacrine Treatment for Prion Diseases. Journal of Virology, 2003, 77, 8462-8469. Structural Properties of Gerstmann-StrÃøssler-Scheinker Disease Amyloid Protein. Journal of Biological Chemistry, 2003, 278, 48146-48153. In vitro Evaluation of the Anti-prionic Activity of Newly Synthesized Congo Red Derivatives. Arzneimittelforschung, 2003, 53, 875-888. Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased	0.7 1.5 1.6	21 14 190 75

#	Article	IF	Citations
217	Tetracyclines affect prion infectivity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10849-10854.	3.3	184
218	Synthetic Miniprion PrP106. Journal of Biological Chemistry, 2002, 277, 31327-31334.	1.6	32
219	Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3505-3510.	3.3	536
220	Wax Esters of n -3 Polyunsaturated Fatty Acids: A New Stable Formulation as a Potential Food Supplement. 1 â€" Digestion and Absorption in Rats. LWT - Food Science and Technology, 2002, 35, 458-465.	2.5	29
221	Characterization of antimalarial SPf66 peptide using MALDI–TOF MS, CD and SEC. Peptides, 2002, 23, 1527-1535.	1.2	4
222	Amidation of \hat{I}^2 -Amyloid Peptide Strongly Reduced the Amyloidogenic Activity Without Alteration of the Neurotoxicity. Journal of Neurochemistry, 2002, 69, 2048-2054.	2.1	34
223	Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Letters, 2001, 487, 404-407.	1.3	205
224	In Vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1327-1332.	1.1	203
225	Studies on peptide fragments of prion proteins. Advances in Protein Chemistry, 2001, 57, 171-201.	4.4	42
226	Purification of the Aldehyde Oxidase Homolog 1 (AOH1) Protein and Cloning of the AOH1 and Aldehyde Oxidase Homolog 2 (AOH2) Genes. Journal of Biological Chemistry, 2001, 276, 46347-46363.	1.6	43
227	The Stimulation of Inducible Nitric-oxide Synthase by the Prion Protein Fragment 106–126 in Human Microglia Is Tumor Necrosis Factor-α-dependent and Involves p38 Mitogen-activated Protein Kinase. Journal of Biological Chemistry, 2001, 276, 25692-25696.	1.6	60
228	A 7-kDa Prion Protein (PrP) Fragment, an Integral Component of the PrP Region Required for Infectivity, Is the Major Amyloid Protein in Gerstmann-StrÃ u ssler-Scheinker Disease A117V. Journal of Biological Chemistry, 2001, 276, 6009-6015.	1.6	119
229	Inhibition of Monocyte Chemotactic Protein-1 Synthesis by Statins. Laboratory Investigation, 2000, 80, 1095-1100.	1.7	282
230	Cloning of the cDNAs Coding for Two Novel Molybdo-flavoproteins Showing High Similarity with Aldehyde Oxidase and Xanthine Oxidoreductase. Journal of Biological Chemistry, 2000, 275, 30690-30700.	1.6	60
231	INHIBITION OF HMG-CoA REDUCTASE ACTIVITY BY HYPERCHOLESTEROLAEMIA REDUCES LEUKOCYTE RECRUITMENT AND MCP-1 PRODUCTION. Cytokine, 2000, 12, 1100-1103.	1.4	11
232	Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro11Edited by J. Karn. Journal of Molecular Biology, 2000, 300, 1309-1322.	2.0	155
233	Apoptotic Cell Death and Impairment of L-Type Voltage-Sensitive Calcium Channel Activity in Rat Cerebellar Granule Cells Treated with the Prion Protein Fragment 106–126. Neurobiology of Disease, 2000, 7, 299-309.	2.1	64
234	Measurement of intracellular calcium levels by the fluorescent Ca2+ indicator Calcium-Green. Brain Research Protocols, 2000, 5, 132-134.	1.7	13

#	Article	IF	Citations
235	Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106–126. International Journal of Developmental Neuroscience, 2000, 18, 481-492.	0.7	56
236	Comment on: Neurotoxicity of prion peptide 106-126 not confirmed, by Beat Kunz, Erika Sandmeier, Philipp Christen. FEBS Letters, 2000, 466, 205-206.	1.3	7
237	Molecular Cloning and Functional Characterization of Brefeldin A-ADP-ribosylated Substrate. Journal of Biological Chemistry, 1999, 274, 17705-17710.	1.6	92
238	Determination of solution conformations of PrP106-126, a neurotoxic fragment of prion protein, by1H NMR and restrained molecular dynamics. FEBS Journal, 1999, 266, 1192-1201.	0.2	32
239	CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid. Nature, 1999, 402, 429-433.	13.7	314
240	Activation of microglial cells by PrP and \hat{I}^2 -amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels. Brain Research, 1999, 818, 168-170.	1.1	101
241	Influence of mutations associated with familial prion-related encephalopathies on biological activity of prion protein peptides. Annals of Neurology, 1999, 45, 489-494.	2.8	20
242	Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. European Journal of Immunology, 1999, 29, 781-788.	1.6	30
243	Localization and age-dependent expression of the inward rectifier K+ channel subunit Kir 5.1 in a mammalian reproductive system. FEBS Letters, 1999, 449, 146-152.	1.3	41
244	Oleamide-mediated sleep induction does not depend on perturbation of membrane homeoviscosity. FEBS Letters, 1999, 463, 281-284.	1.3	10
245	A \hat{I}^2 PP Peptide Carboxyl-Terminal to A \hat{I}^2 Is Neurotoxic. American Journal of Pathology, 1999, 154, 1001-1007.	1.9	18
246	Alteration of SREBP Activation in Liver of Trisomy 21 Fetuses. Biochemical and Biophysical Research Communications, 1999, 260, 499-503.	1.0	12
247	Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106‒126. Biochemical Journal, 1999, 342, 207.	1.7	36
248	Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106–126. Biochemical Journal, 1999, 342, 207-214.	1.7	100
249	Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis. Biochemical Journal, 1999, 344, 7.	1.7	8
250	Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. NeuroReport, 1999, 10, 723-729.	0.6	109
251	Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. , 1998, 54, 341-352.		73
252	Rapid solid-phase extraction method for automated gas chromatographic–mass spectrometric determination of nicotine in plasma. Biomedical Applications, 1998, 707, 312-316.	1.7	18

#	Article	IF	CITATIONS
253	PrP Peptides as a Tool to Investigate the Pathogenesis of Prion Protein Amyloidoses. , 1998, , 285-289.		O
254	Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3. Journal of Biological Chemistry, 1997, 272, 32817-32823.	1.6	353
255	Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor. Mediators of Inflammation, 1997, 6, 32-38.	1.4	70
256	Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters. Science, 1997, 276, 1119-1121.	6.0	168
257	A Neurotoxic and Gliotrophic Fragment of the Prion Protein Increases Plasma Membrane Microviscosity. Neurobiology of Disease, 1997, 4, 47-57.	2.1	60
258	[[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone Derivatives as High-Affinity, Selective 5-HT1AReceptor Ligandsâ€. Journal of Medicinal Chemistry, 1997, 40, 574-585.	2.9	67
259	Identification of a Short Sequence Highly Divergent Between beta-Adrenergic-Receptor Kinases 1 and 2 that Determines the Affinity of Binding to betagamma Subunits of Heterotrimeric Guanine-Nucleotide-Binding Regulatory Proteins. FEBS Journal, 1997, 245, 533-540.	0.2	11
260	Spectroscopic and binding studies on the interaction of inorganic anions with lactoperoxidase. Journal of Inorganic Biochemistry, 1997, 68, 17-26.	1.5	42
261	Amyloid in alzheimer's disease and prion-related encephalopathies: Studies with synthetic peptides. Progress in Neurobiology, 1996, 49, 287-315.	2.8	54
262	Intracellular Calcium Rise through L-Type Calcium Channels, as Molecular Mechanism for Prion Protein Fragment 106-126-Induced Astroglial Proliferation. Biochemical and Biophysical Research Communications, 1996, 228, 397-405.	1.0	76
263	In vivo exposure to NO2 reduces TNF and IL-6 production by endotoxin-stimulated alveolar macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1996, 271, L132-L138.	1.3	6
264	Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes. Biochemical Journal, 1996, 320, 563-570.	1.7	49
265	A theoretical three-dimensional model for lactoperoxidase and eosinophil peroxidase, built on the scaffold of the myeloperoxidase X-ray structure. Journal of Biological Inorganic Chemistry, 1996, 1, 476-485.	1.1	35
266	Apoptosis-mediated neurotoxicity induced by \hat{l}^2 -amyloid and PRP fragments. Molecular and Chemical Neuropathology, 1996, 28, 163-171.	1.0	90
267	Clusterin (SGP-2) Induction in Rat Astroglial Cells Exposed to Prion Protein Fragment 106-126. European Journal of Neuroscience, 1996, 8, 589-597.	1.2	37
268	β25–35 Alters Calcium Homeostasis and Induces Neurotoxicity in Cerebellar Granule Cells. Journal of Neurochemistry, 1996, 66, 1995-2003.	2.1	38
269	Manganese Peroxidase from Phanerochaete chrysosporium. A Homology-Based Molecular Model. FEBS Journal, 1995, 228, 955-961.	0.2	3
270	Basic proteins and basic membranes adjusting blotting and staining conditions to immobilon CD. Journal of Chromatography A, 1995, 698, 351-359.	1.8	2

#	Article	IF	CITATIONS
271	Purification, cDNA Cloning, and Tissue Distribution of Bovine Liver Aldehyde Oxidase. Journal of Biological Chemistry, 1995, 270, 31037-31045.	1.6	96
272	Phosphatidic Acid and Lysophosphatidic Acid Induce Haptotactic Migration of Human Monocytes. Journal of Biological Chemistry, 1995, 270, 25549-25556.	1.6	90
273	Reye's and Reye-Like Syndromes, Drug-Related Diseases? (Causative Agents, Etiology, Pathogenesis, and) Tj ETQq	l 1 0.7843 1.5	34 rgBT /C
274	Extracellular glutamate levels in the hypothalamus and hippocampus of rats after acute or chronic oral intake of monosodium glutamate. Neuroscience Letters, 1995, 193, 45-48.	1.0	24
275	The Purification of Histones by Metal-Chelate Chromatography. Analytical Biochemistry, 1994, 222, 505-507.	1.1	2
276	The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. International Journal of Cancer, 1994, 57, 645-649.	2.3	43
277	In vivo anti-tumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition. International Journal of Cancer, 1994, 59, 580-581.	2.3	1
278	An automated system for animal exposure to nitrogen dioxide. Journal of Pharmacological and Toxicological Methods, 1994, 31, 187-190.	0.3	1
279	A Neurotoxic Prion Protein Fragment Induces Rat Astroglial Proliferation and Hypertrophy. European Journal of Neuroscience, 1994, 6, 1415-1422.	1.2	112
280	Solubilization and characterization of d-fenfluramine binding sites from bovine cerebral cortex. Life Sciences, 1994, 54, 1109-1118.	2.0	3
281	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. Kidney International, 1993, 44, 747-754.	2.6	1
282	Neurotoxicity of a prion protein fragment. Nature, 1993, 362, 543-546.	13.7	935
283	Effect of cell density on cytotoxicity of ether lipid analogues in variants of B16 murine melanoma. Lipids, 1993, 28, 403-406.	0.7	1
284	The effect of culture medium composition on ether lipid cytotoxic activity. Lipids, 1993, 28, 189-192.	0.7	14
285	The pneumotoxicant paraquat induces IL-8 mRNA in human mononuclear cells and pulmonary epithelial cells. Cytokine, 1993, 5, 525-530.	1.4	24
286	Molecular Characteristics of a Protease-Resistant, Amyloidogenic and Neurotoxic Peptide Homologous to Residues 106-126 of the Prion Protein. Biochemical and Biophysical Research Communications, 1993, 194, 1380-1386.	1.0	212
287	Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-RAC-glycero-3-phosphocholine. A possible basis for its selective action. International Journal of Cancer, 1993, 53, 124-130.	2.3	112
288	Fetal lung maturity evaluation with fluorescence polarization of the amniotic fluid. Journal of Perinatal Medicine, 1993, 21, 349-354.	0.6	2

#	Article	IF	Citations
289	Apoptosis mediated neurotoxicity induced by chronic application of \hat{l}^2 amyloid fragment 25 \hat{a} €"35. NeuroReport, 1993, 4, 523-526.	0.6	355
290	Reactive Oxygen Intermediates in Tumor Necrosis Factor Production and Endotoxic Shock. , 1993 , , $113-119$.		0
291	Role of Surfactant in Chronic Obstructive Pulmonary Disease: Therapeutic Implications. Respiration, 1992, 59, 28-32.	1.2	50
292	Effect of Ambroxol on Rabbit Eustachian Tube Surfactant. Orl, 1992, 54, 130-132.	0.6	0
293	A soluble form of prion protein in human cerebrospinal fluid: Implications for prion-related encephalopathies. Biochemical and Biophysical Research Communications, 1992, 184, 1398-1404.	1.0	90
294	A novel pharmacological approach for paraquat poisoning in rat and A549 cell line using ambroxol, a lung surfactant synthesis inducer. Food and Chemical Toxicology, 1992, 30, 789-794.	1.8	26
295	Modulation of ATPase activity by cholesterol and synthetic ether lipids in leukemic cells. Biochemical Pharmacology, 1992, 43, 803-807.	2.0	19
296	Synthetic ether lipids fluidizing action and cell membrane lipid composition: A commentary note. International Journal of Cancer, 1992, 52, 162-163.	2.3	3
297	Aging and food restriction: Effect on lipids of cerebral cortex. Neurobiology of Aging, 1991, 12, 55-59.	1.5	55
298	Effect of tyrosine on the potentiation by aspartame and phenylalanine of metrazol-induced convulsions in rats. Food and Chemical Toxicology, 1991, 29, 855-857.	1.8	4
299	Interspecies and interstrain studies on the increased susceptibility to metrazol-induced convulsions in animals given aspartame. Food and Chemical Toxicology, 1991, 29, 101-106.	1.8	17
300	Effect of Iodinated Contrast Media on the Synthesis and Metabolism of Leukotriene B4. Investigative Radiology, 1991, 26, 348-352.	3.5	4
301	Increased ether lipid cytotoxicity by reducing membrane cholesterol content. International Journal of Cancer, 1991, 49, 409-413.	2.3	25
302	Protection against acute paraquat toxicity by ambroxol. Cytotechnology, 1991, 5, 25-27.	0.7	2
303	Disaturated Phosphatidylcholine in Rabbit Eustachian Tube Surfactant. Orl, 1990, 52, 174-179.	0.6	5
304	Effect of Iodinated Contrast Media on the Synthesis and Metabolism of Leukotriene B4. Investigative Radiology, 1990, 25, S25-S26.	3.5	2
305	Fluorescence Polarization Changes with Gestational Age in Amniotic Fluid of Rabbit and Guinea Pig. Experimental Lung Research, 1990, 16, 507-519.	0.5	0
306	Oral zeranol shortens the prolonged bleeding time of uremic rats. Kidney International, 1990, 38, 96-100.	2.6	5

#	Article	IF	CITATIONS
307	Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects and cytotoxicity. International Journal of Cancer, 1990, 46, 341-346.	2.3	55
308	Determination of argininosuccinate lyase and arginase activities with an amino acid analyzer. Analytical Biochemistry, 1990, 191, 384-389.	1.1	15
309	Interferon inducers increase O6-alkylguanine-DNA alkyltransferase in the rat liver. Carcinogenesis, 1990, 11, 181-183.	1.3	16
310	Plasma and brain kinetics of large neutral amino acids and of striatum monoamines in rats given aspartame. Food and Chemical Toxicology, 1990, 28, 317-321.	1.8	13
311	Effect of ambroxol on surfactant of rabbit eustachian tube. European Journal of Pharmacology, 1990, 183, 725-726.	1.7	0
312	Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. International Journal of Cancer, 1989, 44, 707-713.	2.3	99
313	Effect of aspartame on seizures in various models of experimental epilepsy. Toxicology and Applied Pharmacology, 1988, 96, 485-493.	1.3	14
314	Liver DNA alkylation after a single carcinogenic dose of dimethylnitrosamine to newborn and adult CFW Swiss mice. Chemico-Biological Interactions, 1988, 68, 259-271.	1.7	23
315	A rapid electrochemical assay of lecithin in amniotic fluid using a fluoride ion-sensitive electrode. Clinica Chimica Acta, 1988, 172, 161-169.	0.5	5
316	Differential effects of benzodiazepines on phospholipid methylation in hippocampus and cerebellum of rats. Life Sciences, 1988, 42, 525-531.	2.0	3
317	Aspartame and the rat brain monoaminergic system. Toxicology Letters, 1988, 44, 331-339.	0.4	18
318	Role of Alveolar Phospholipids in Bleomycin-Induced Pulmonary Fibrosis in the Rat. Respiration, 1987, 51, 23-32.	1.2	10
319	Defective Production of Reactive Oxygen Intermediates by Tumor-Associated Macrophages Exposed to Phorbol Ester. Journal of Leukocyte Biology, 1987, 42, 84-90.	1.5	9
320	Measurement of fetal surfactant production by fluorescence polarization of amniotic fluid in complicated pregnancies. Clinica Chimica Acta, 1987, 168, 137-142.	0.5	5
321	In vivo studies of rat alveolar macrophase microviscosity: Influence of pulmonary surfactant synthesis stimulation. Lung, 1987, 165, 333-340.	1.4	4
322	DNA synthesis, mitotic index, drug-metabolising systems and cytogenetic analysis in regenerating rat liver. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1987, 182, 75-82.	0.4	19
323	Determination of fetal lung maturity in rats by fluorescence polarization. Biochemical Pharmacology, 1986, 35, 1259-1261.	2.0	3
324	Gentisic acid: an aspirin metabolite with multiple effects on human blood polymorphonuclear leukocytes. Biochemical Pharmacology, 1986, 35, 2443-2445.	2.0	22

#	Article	lF	Citations
325	N-acetyl- \hat{l}^2 -d-glucosaminidase (NAC) levels in amniotic fluid or urine in prenatal and postnatal life. Early Human Development, 1986, 14, 229-232.	0.8	9
326	Biochemical characterization of the hepatic effects in mice and rats of 1,4-bis62-(3,5-dichloropyridyloxy)9benzene, a hepatic neoplasm promoter. Toxicology and Applied Pharmacology, 1986, 83, 379-385.	1.3	11
327	The rate of N-demethylation of N, N-dimethylanilines and N-methylanilines by rat-liver microsomes is related to their first ionization potential, their lipophilicity and to a steric bulk factor. Xenobiotica, 1986, 16, 511-517.	0.5	31
328	Prostaglandins and aminoglycoside nephrotoxicity. Toxicology and Applied Pharmacology, 1985, 78, 386-394.	1.3	19
329	Tumor-derived chemotactic factor(S) from human ovarian carcinoma: Evidence for a role in the regulation of macrophage content of neoplastic tissues. International Journal of Cancer, 1985, 36, 167-173.	2.3	59
330	Platelet derived growth factor induces ornithine decarboxylase activity in nih 3T3 cells. Biochemical and Biophysical Research Communications, 1985, 127, 843-848.	1.0	11
331	Kinetics of monosodium glutamate in human volunteers under different experimental conditions. Food and Chemical Toxicology, 1985, 23, 975-978.	1.8	5
332	Intact human lymphocyte membranes respond to muscarinic receptor stimulation by oxotremorine with marked changes in microviscosity and an increase in cyclic GMP. FEBS Letters, 1985, 192, 194-198.	1.3	23
333	Structure reactivity relationships in the microsomal oxidation of tertiary amines. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 289-293.	0.6	17
334	Different susceptibility of mouse tissues to porphyrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicology Letters, 1984, 20, 201-210.	0.4	7
335	Diazepam increases membrane fluidity of rat hippocampus synaptosomes. FEBS Letters, 1984, 173, 255-258.	1.3	27
336	Characterization of arachidonic acid metabolic profiles in animal tissues by high-resolution gas chromatography-mass spectrometry. Lipids and Lipid Metabolism, 1984, 794, 292-297.	2.6	21
337	Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochemical and Biophysical Research Communications, 1984, 119, 144-149.	1.0	83
338	Kinetics of 3-tert-butyl-4-hydroxyanisole (BHA) in man. Food and Chemical Toxicology, 1984, 22, 901-904.	1.8	14
339	Perinatal development of styrene monooxygenase and epoxide hydrolase in rat liver microsomes and nuclei. Chemico-Biological Interactions, 1983, 47, 213-222.	1.7	7
340	Mutagenic relevance of rat hepatocyte nuclei in the activation and inactivation of xenobiotica cyclophosphamide and epichlorohydrin activity on the yeasts S. pombe and S. cerevisiae. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1983, 111, 313-323.	0.4	2
341	Evaluation of epichlorohydrin (ECH) genotoxicity. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1983, 109, 41-52.	0.4	12
342	Styrene oxidation to styrene oxide in human erythrocytes is catalyzed by oxyhemoglobin. Experientia, 1983, 39, 593-594.	1.2	31

#	Article	IF	Citations
343	Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues. International Journal of Cancer, 1983, 31, 55-63.	2.3	55
344	The influence of selenium intake on chronic adriamycin toxicity and lipid peroxidation in rats. Toxicology Letters, 1983, 15, 301-307.	0.4	25
345	Plasma pyroglutamic acid levels after oral administration of monosodium glutamate to human volunteers. Toxicology Letters, 1983, 15, 123-129.	0.4	10
346	Pyroglutamate kinetics and neurotoxicity studies in mice. Toxicology Letters, 1983, 16, 225-229.	0.4	8
347	Toxicological evaluation of urban waste incinerator emissions. Chemosphere, 1983, 12, 559-564.	4.2	18
348	N-Acetyl- \hat{l}^2 -d-glucosaminidase (NAG) and NAG isoenzymes in children with upper and lower urinary tract infections. Clinica Chimica Acta, 1983, 130, 297-304.	0.5	28
349	Is There a Role for Nuclei in the Metabolism of Xenobiotica? A Review. Drug Metabolism Reviews, 1983, 14, 803-829.	1.5	24
350	Further studies on adriamycin induced in vitro lipid peroxidation. Chemico-Biological Interactions, 1982, 38, 357-367.	1.7	13
351	Perinatal development of cytochrome P-450, nadphcytochrome c reductase and ethoxycoumarin deethylase in rat liver nuclear membranes. Chemico-Biological Interactions, 1982, 42, 225-231.	1.7	7
352	Determination of dipeptides in protein hydrolysates for total parenteral nutrition. Journal of Chromatography A, 1982, 246, 334-339.	1.8	5
353	Regulation of Macrophage Functions by Interferon. Advances in Experimental Medicine and Biology, 1982, 155, 519-524.	0.8	2
354	Methodological and clinical aspects of urinary N-acetyl-glucosaminidase in pediatric subjects. Biochemical Medicine, 1981, 25, 26-33.	0.5	23
355	Plasma kinetics and urinary elimination of saccharin in man. Toxicology Letters, 1981, 9, 367-371.	0.4	9
356	GLC-mass Fragmentographic Determination of Saccharin in Biological Fluids. Journal of Pharmaceutical Sciences, 1981, 70, 871-874.	1.6	3
357	Induction of nuclear styrene monooxygenase and epoxide hydrolase in rat liver. Experientia, 1981, 37, 230-231.	1.2	2
358	Induction of mixed-function oxidase by chronic treatment with 2,3,7,8-tetrachloro-dibenzo-p-dioxin in female rats. Toxicology, 1981, 21, 159-167.	2.0	6
359	Porphyrogenic effect of chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin in female rats. Dose-effect relationship following urinary excretion of porphyrins. Toxicology and Applied Pharmacology, 1981, 57, 156-163.	1.3	40
360	Nuclear metabolism. II. Further studies on epoxide hydrolase activity. Chemico-Biological Interactions, 1981, 35, 311-318.	1.7	11

#	Article	IF	CITATIONS
361	Improved gas chromatographic method for measuring phenylethylene glycol. Journal of Chromatography A, 1980, 188, 400-404.	1.8	20
362	Is nuclear styrene monooxygenase activity a microsomal artifact?. Chemico-Biological Interactions, 1980, 31, 341-346.	1.7	9
363	Nuclear metabolism. I. Determination of styrene monooxygenase activity in rat liver nuclei. Chemico-Biological Interactions, 1980, 29, 189-195.	1.7	11
364	Non-linear kinetics of microsomal styrene monooxygenase after phenobarbital pre-treatment. Experientia, 1980, 36, 640-641.	1.2	5
365	Monosodium glutamate kinetic studies in human volunteers. Toxicology Letters, 1980, 5, 417-421.	0.4	14
366	Effect of oral monosodium glutamate on glutamic acid levels in the nucleus arcuatus of the hypothalamus and on serum osmolality of adult and infant mice. Toxicology Letters, 1980, 7, 107-111.	0.4	11
367	Effects of chronic treatment with DI-(2-ethylhexyl) phthalate on rat liver microsomal activities. Toxicology Letters, 1980, 6, 51-58.	0.4	5
368	In vitro effects of saccharin on cell-mediated host defence mechanisms. Toxicology Letters, 1980, 5, 287-295.	0.4	10
369	Plasma glutamic acid levels in premature newborn. Toxicology Letters, 1980, 5, 197-201.	0.4	1
370	Quantitative gas-liquid chromatographic determination of ftorafur and 5-fluorouracil in biological specimens. Analytical Biochemistry, 1979, 97, 232-238.	1.1	12
371	Quantitative thin-layer chromatographic measurement of N-trifluoroacetyladriamycin-14-valerate (AD) Tj ETQq1 1	0.78431 1.7	4 rgBT /Ov <mark>er</mark> 7
372	Ftorafur: A self-limiting source of 5-fluorouracil?. Cancer Chemotherapy and Pharmacology, 1979, 3, 61-66.	1.1	10
373	Decreased half life of cyclophosphamide in patients under continual treatment. European Journal of Cancer, 1979, 15, 7-10.	1.0	65
374	Isolation and structure determination of enzymatically formed styrene oxide glutathione conjugates. Chemico-Biological Interactions, 1979, 27, 313-321.	1.7	25
375	Glutamic acid and sodium levels in the nucleus arcuatus of the hypothalamus of adult and infant rats after oral monosodium glutamate. Toxicology Letters, 1979, 3, 121-126.	0.4	7
376	The absorption by human volunteers of glutamic acid from monosodium glutamate and from a partial enzymic hydrolysate of casein. Toxicology, 1978, 11, 101-107.	2.0	13
377	Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen—phosphorus-selective detector. Biomedical Applications, 1978, 145, 315-318.	1.7	19
378	Intercalation with DNA is a prerequisite for Daunomycin, Adriamycin and its congeners in inhibiting DNAase I. Chemico-Biological Interactions, 1978, 20, 97-102.	1.7	28

#	Article	IF	CITATIONS
379	Degradation of 2,3,7,8-tetrachlorodibenzo-p-dioxin in organic solvents by gamma ray irradiation. Experientia, 1978, 34, 1126-1127.	1.2	8
380	The oral administration of msg at varying concentrations to male mice. Toxicology Letters, 1978, 1, 195-199.	0.4	4
381	Uptake of glutamate in beagle dogs after oral gavage with MSG. Toxicology Letters, 1978, 2, 305-311.	0.4	6
382	Hepatic and extrahepatic formation and hydration of styrene oxide in vitro in animals of different species and sex. Toxicology Letters, 1978, 2, 179-186.	0.4	59
383	Serum glutamate in rhesus macaques after gavage with MSG. Toxicology Letters, 1978, 2, 299-303.	0.4	6
384	Kinetics of monosodium glutamate in relation to its neurotoxicity. Toxicology Letters, 1977, 1, 123-130.	0.4	26
385	Effect of daunomycin, adriamycin and its congener AD 32 on the activity of DNase I from bovine pancreas. Biochemical Pharmacology, 1977, 26, 1953-1954.	2.0	9
386	Inhibition of liver microsomal epoxide hydrase by cyproheptadine epoxide. Experientia, 1977, 33, 484-485.	1.2	3
387	Kinetic behaviour of microsomal styrene monooxygenase and styrene epoxide hydratase in different animal species. Experientia, 1977, 33, 708-709.	1.2	20
388	In vitro binding and metabolism of iopronic acid by rat liver microsomes. Pharmacological Research Communications, 1977, 9, 833-846.	0.2	11
389	Uptake of 14C-5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. Naunyn-Schmiedeberg's Archives of Pharmacology, 1976, 296, 59-65.	1.4	51
390	A specific gas chromatographic method for the determination of microsomal styrene monooxygenase and styrene epoxide hydratase activities. Journal of Chromatography A, 1976, 118, 387-393.	1.8	61
391	Microsomal Styrene Mono-oxygenase and Styrene Epoxide Hydrase Activities in Rats. Xenobiotica, 1976, 6, 585-591.	0.5	43
392	Activity of liver microsomal mono-oxygenases on some epoxide-forming tricyclic drugs. I. Kinetics <i>in vitro</i> . Xenobiotica, 1976, 6, 593-598.	0.5	13
393	Relationship of In Vitro Hydrolysis of 17â€Chloroacetylajmaline and 17â€Acetylajmaline in Different Animal Species. Journal of Pharmaceutical Sciences, 1975, 64, 1561-1563.	1.6	1
394	Gas chromatographic-mass spectrometric determination of intact C3-hydroxylated benzodiazepine glucuronides in urine. Journal of Chromatography A, 1975, 107, 285-293.	1.8	15
395	In Vitro Hydrolysis of Oxazepam Succinate Half-Ester by a Stereospecific Soluble Esterase from Different Animal Species. Journal of Pharmaceutical Sciences, 1974, 63, 222-225.	1.6	29
396	Therapeutic Approaches to Prion Diseases: In Vitro Studies with Tetracycline Compounds., 0,, 809-820.		1

#	Article	IF	CITATIONS
397	NMR-Driven Identification of Cinnamon Bud and Bark Components With Anti-Al 2 Activity. Frontiers in Chemistry, 0, 10, .	1.8	6